For patients who have contracted COVID, CureLab Oncology intends to determine how Elenagen can be used to reduce mortality and life-threatening complications, and to shorten time to recovery.

Matt Pillar’s feature on BioCube captures how the buzzing biotech accelerator is winning the hearts and minds of Silicon Valley biotech startups.

This latest 67,000-square-foot addition to Silicon Valley’s biotech scene provides a hive-like setting for up to 50 life-science startups that range from small to mid-size.

An industry first, Taliware’s Biombeat launches an SDK so that developers can combine a person’s ECG biometrics with geolocation for maximum security.

Senturion+ launches an advanced, natural material called Viruend that catches and kills at least 25% more SARS-CoV-2 and other viruses than standard N95 masks.

CureLab Oncology forms veterinary oncology subsidiary to fight pet cancer—and gain valuable insights into the mechanism of its Elenagen™ gene therapy

rBIO's platform for synthetic insulin achieves success as the team looks to production scale-up and a range of other prescription drugs to target.

With BioCube’s cool wet labs now up and running, the next wave of budding biotech companies have a good reason to locate closer to San Jose.

The pre-IND briefing package was centered around a proposed Phase II US clinical trial for CureLab’s experimental cancer-fighting DNA vaccine.

Following Transform Materials’ recent launch, Chemical Engineering profiled CEO Dr. David Soane in the November edition.

CureLab is developing an investigational DNA vaccine called Elenagen, which reverses tumor grade, changes tumor microenvironment, and stimulates an immune attack on the tumor.

ZingPR and Bioinsider convene biotech experts to network, exchange ideas and address timely issues in science and healthcare.

The Therapeutic Pipeline for COVID-19 meeting was the second in Bioinsider’s ‘Together as One’ COVID-19 Virtual Meeting Series. It brought together more than 100 researchers and featured 11 keynote presentations focused on small-molecule and antibody-based approaches. Here’s what we learned.

Biovista applies AI and data science to identify two drugs as potentially effective therapies for blood clots and inflammation caused by COVID-19. That’s six treatments identified to date!

Dr. Michael Chen talks about how his research can be applied to addressing the complications associated with COVID-19

PEEL co-founder and CEO Dr. Joshua Schiffman talks about how his research into babies and elephants can address the complications associated with COVID-19.